Ys Biopharma Co, Stock Current Valuation
| YSDelisted Stock | 0.48 0.03 5.88% |
Valuation analysis of YS Biopharma Co, helps investors to measure YS Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that YS Biopharma's price fluctuation is very steady at this time. Calculation of the real value of YS Biopharma Co, is based on 3 months time horizon. Increasing YS Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the YS Biopharma stock is determined by what a typical buyer is willing to pay for full or partial control of YS Biopharma Co,. Since YS Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of YS Biopharma Stock. However, YS Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.48 | Real 0.46 | Hype 0.48 | Naive 0.5 |
The intrinsic value of YS Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence YS Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of YS Biopharma Co, helps investors to forecast how YS Biopharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of YS Biopharma more accurately as focusing exclusively on YS Biopharma's fundamentals will not take into account other important factors: YS Biopharma Co, Company Current Valuation Analysis
YS Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current YS Biopharma Current Valuation | 429.47 M |
Most of YS Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, YS Biopharma Co, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, YS Biopharma Co, has a Current Valuation of 429.47 M. This is 97.01% lower than that of the Biotechnology sector and 90.76% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.42% higher than that of the company.
YS Biopharma Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses YS Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of YS Biopharma could also be used in its relative valuation, which is a method of valuing YS Biopharma by comparing valuation metrics of similar companies.YS Biopharma is currently under evaluation in current valuation category among its peers.
YS Biopharma Fundamentals
| Return On Equity | -0.78 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.67) % | |||
| Operating Margin | (0.49) % | |||
| Current Valuation | 429.47 M | |||
| Shares Outstanding | 188.33 M | |||
| Shares Owned By Insiders | 81.42 % | |||
| Shares Owned By Institutions | 2.85 % | |||
| Number Of Shares Shorted | 38.89 K | |||
| Price To Book | 2.10 X | |||
| Price To Sales | 0.29 X | |||
| Revenue | 687.2 M | |||
| EBITDA | (76.82 M) | |||
| Net Income | (145.48 M) | |||
| Total Debt | 498.63 M | |||
| Book Value Per Share | 5.10 X | |||
| Cash Flow From Operations | (182.47 M) | |||
| Short Ratio | 0.31 X | |||
| Earnings Per Share | (0.56) X | |||
| Target Price | 4.17 | |||
| Number Of Employees | 773 | |||
| Beta | 0.54 | |||
| Market Capitalization | 192.09 M | |||
| Total Asset | 1.72 B | |||
| Retained Earnings | (1.87 B) | |||
| Working Capital | 377.22 M | |||
| Net Asset | 1.72 B |
About YS Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze YS Biopharma Co,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma Co, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma Co, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |